RSV prevention drug under watch: 3000 korean kids monitored for safety
NCT ID NCT07200206
Summary
This study is monitoring the safety of Beyfortus, a drug given to prevent severe RSV infections in infants and young children. It will follow 3,000 Korean children under 2 years old for 6 months after they receive the injection in real-world medical settings. The main goal is to track any side effects or health problems that occur after the drug is given.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nam Seung Woo Pediatric: 4100007
RECRUITINGHwaseong-si, Gyeonggi-do, 18478, South Korea
Conditions
Explore the condition pages connected to this study.